DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

NCT05722886 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

825

Enrollment

OTHER

Sponsor class

Conditions

Haematological Malignancy
Solid Tumour

Interventions

DRUG: Alectinib
DRUG: Atezolizumab
DRUG: Entrectinib
DRUG: Trastuzumab in combination with pertuzumab
DRUG: Vemurafenib in combination with cobimetinib
DRUG: Capmatinib

Sponsor

Cancer Research UK

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]